NICE says ‘yes’ to Remicade, Humira and Simponi for ulcerative colitis

12 December 2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued its final appraisal document (FAD) on Merck & Co’s (NYSE: MRK) Remicade (infliximab) and Simponi (golimumab), and AbbVie’s (NYSE: ABBV) Humira (adalimumab)

The drugs are recommended within their marketing authorizations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.

Simponi is recommended only if Merck Sharpe & Dohme (the trading name for Merck’s non-North American business) provides the 100mg dose at the same cost as the 50mg dose, as agreed in the patient access scheme. Final guidance on the use of infliximab, adalimumab and golimumab as treatments for ulcerative colitis is expected to be published January 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK